Zimmer Biomet (ZBH) Stock Forecast & Price Target

$108.69 -1.48 (-1.34%)

(As of 11/7/2024 ET)

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
2

Hold
12

Buy
7

Based on 21 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 12 have given a hold rating, and 7 have given a buy rating for ZBH.

Consensus Price Target

$124.11
14.18% Upside

According to the 21 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $124.11. The highest price target for ZBH is $150.00, while the lowest price target for ZBH is $107.00. The average price target represents a forecasted upside of 14.18% from the current price of $108.69.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

ZBH Analyst Ratings Over Time

Type	Current Forecast 11/8/23 to 11/7/24	1 Month Ago 10/9/23 to 10/8/24	3 Months Ago 8/10/23 to 8/9/24	1 Year Ago 11/8/22 to 11/8/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	10 Hold rating(s)	9 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$124.11	$124.53	$127.67	$141.33
Forecasted Upside	14.18% Upside	22.36% Upside	18.12% Upside	34.78% Upside
Consensus Rating	Hold	Hold	Hold	Hold

Bill Gates’s Next Big AI Bet: Stargate (Ad)

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Medical Companies	S&P 500
Consensus Rating Score	2.24	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	13.78% Upside	9,983.19% Upside	7.16% Upside
News Sentiment Rating	Neutral News See Recent ZBH News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/4/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$120.00 ➝ $125.00	+16.16%
11/1/2024	Truist Financial 2 of 5 stars		Boost Target	Hold ➝ Hold	$112.00 ➝ $117.00	+8.17%
10/31/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $117.00	+9.43%
10/31/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
10/15/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$145.00 ➝ $135.00	+29.93%
10/14/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$128.00 ➝ $123.00	+17.69%
Get the Latest News and Ratings for ZBH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.
10/3/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$134.00 ➝ $126.00	+20.56%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$113.00 ➝ $110.00	+2.31%
9/16/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$125.00 ➝ $120.00	+12.46%
9/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$120.00 ➝ $115.00	+10.09%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
9/6/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$143.00 ➝ $119.00	+13.61%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sell ➝ Sell	$112.00 ➝ $107.00	-0.07%
8/8/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$155.00 ➝ $145.00	+37.01%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$130.00 ➝ $120.00	+12.21%
7/10/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$134.00 ➝ $120.00	+12.25%
7/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. O'brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $115.00	+5.96%
5/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$130.00 ➝ $125.00	+9.39%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$129.00	+12.04%
5/21/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+25.89%
11/13/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Outperform ➝ Market Outperform	$160.00 ➝ $140.00	+31.14%
10/20/2023	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$120.00	+14.56%
5/18/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/18/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$160.00 ➝ $165.00	+22.19%
5/3/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/3/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$121.00 ➝ $147.00	+4.13%
5/3/2023	FIG Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral
5/3/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
5/3/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$136.00 ➝ $152.00	+6.29%
3/31/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Hold	$115.00 ➝ $130.00	+2.56%
2/6/2023	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$125.00 ➝ $140.00	+8.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:37 PM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 29, 2024. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

Zimmer Biomet has a market capitalization of $21.69 billion, indicating a strong presence and stability in the market.
The company's P/E ratio of 23.06 suggests that investors are willing to pay $23.06 for every $1 of earnings, which could indicate growth potential.
Recent quarterly earnings report showed Zimmer Biomet beating the consensus estimate, indicating strong financial performance.
With a dividend yield of 0.90%, investors can benefit from a steady income stream through Zimmer Biomet's dividend payments.
The company's revenue growth of 3.9% compared to the same quarter last year shows positive momentum in its business operations.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

The company's quick ratio of 0.63 and debt-to-equity ratio of 0.31 may indicate potential liquidity and financial leverage concerns.
Zimmer Biomet's stock has a 12-month low of $102.00, which could pose a risk for investors in terms of potential price volatility.
The 50-day simple moving average of $109.86 is below the 200-day simple moving average of $115.11, potentially signaling a short-term bearish trend.
The PEG ratio of 1.97 may suggest that the stock is overvalued relative to its earnings growth potential.
Despite a positive revenue growth, Zimmer Biomet's net margin of 13.25% may be lower than expected, impacting profitability.

ZBH Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $124.11, with a high forecast of $150.00 and a low forecast of $107.00.
: 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 2 sell ratings, 12 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
: According to analysts, Zimmer Biomet's stock has a predicted upside of 14.18% based on their 12-month stock forecasts.
: Zimmer Biomet has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Evercore ISI, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, Raymond James, Royal Bank of Canada, TD Cowen, Truist Financial, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZBH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Watch this before it gets removed (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

This page (NYSE:ZBH) was last updated on 11/7/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Stock Forecast & Price Target